Table 3.

Priority scores of glioblastoma immunotherapeutics in preclinical studies.

					Adoptive cellular
Therapeutic agent			STAT3 inhibitor	EGFRvIII × CD3 bispecific monoclonal Ab	*EGFRvIII CAR	*EGFRCAR	*IDH1 peptide vaccine	4-1BB aptamer	*Arginine	*IDO inhibitor	Adv-TK + Adv-Flt3L
Antigen/ Target	Expression frequency	0–33% (1)34–66% (2)66–100 (3)	272	123-25	123-25	226,128,129	185,86			3201,202
	Benefit in other malignancy	1	1203-211
	Homogeneous expression	1				126,128,129
	Persistence at recurrence	2	2212	2152,153	2152,153	226,128,129	285,86
	Mechanism of resistance	1	1212	1152,153	1152,153	126,128,129				1202
	Specificity of expression in the tumor			123-25	123-25		185,86,213
Immune activation and effector response	Immune activation	1	1111,214	184,215	169,216	1217	187,218	1172,219-221	1109,110		195,96
	Trafficking to the tumor	1	1214,222	184,215	166-68,216	1223	187,218	1224			195,96
	Maintenance of effector response within tumor	1	0214	184,215	166,67,216		187	1172	1110		195,96
Agent: Preclinical	Anti-stem cell activity	2	27,79-81			2223
	Efficacy in preclinical models	Other (1)Clone (1)*GEMM/Xenograft (2)	1111,214 17,76,80,111,210,2142112,225	284,215	166-69266-69,216	12172223	1218287,218	1219,224,2262172,224		120228,202	195296
	Acceptable toxicity profile	2	278,112,225	284,215	266-68,216	2217,223	287,218	2172,224,227	2228	28	295,96
	Hits target in vivo	2	2112,210,225	284,215	266-68,216	2223	287,218			28	295,96
Score			20	14	15	17	14	8	4	11	10

Abbreviation: *GEMM, genetically-engineered murine model (of glioma).